Oncofolic 50 mg/ml

DRUG2 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Scandion Oncology A/S

Conditions

HER2-positiveMetastatic Colorectal Cancerlocalized esophagogastric adenocarcinoma

Phase 2

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT

Active, not recruitingCTIS2024-513610-34-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHHER2-positive, localized esophagogastric adenocarcinoma

Start: 2023-02-13Target: 30Updated: 2025-06-30

An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient treatment modality in metastatic or advanced colorectal cancer (mCRC) patients with acquired FOLFIRI resistant cancer disease

Active, not recruitingCTIS2024-518877-33-00

Scandion Oncology A/SMetastatic Colorectal Cancer

Start: 2022-03-17Target: 31Updated: 2024-11-19